Jenburkt Pharmaceuticals Limited has formally published its standalone audited financial results for the quarter and financial year ended on March 31, 2026. The announcement was made in compliance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was communicated to BSE Ltd. on May 6, 2026.

Board Approval and Regulatory Compliance

The Board of Directors of Jenburkt Pharmaceuticals convened on Tuesday, May 5, 2026, and approved the standalone audited financial results for the quarter and financial year ended on March 31, 2026. The filing was submitted to BSE Ltd. under Script Code 524731, with the formal intimation letter bearing reference number JPL/CS/2308/2025, signed by Ashish R. Shah, Sr. Vice President, Company Secretary, and Compliance Officer.

Newspaper Publications

In accordance with regulatory requirements, the standalone audited financial results were published in the following newspapers on May 6, 2026:

• The Free Press Journal, Mumbai (English)
• Navshakti, Mumbai (Marathi)

These publications serve as the official public disclosure of the company's audited financial results for the relevant period.

Availability of Financial Results

The complete financial results of Jenburkt Pharmaceuticals are available for public access through the following channels:

• BSE India website: www.bseindia.com
• Company website: https://jenburkt.com/investors/financial-results

Stakeholders and investors may access the full format of the financial results through either of these platforms. The company has also made the results accessible via a Quick Response (QR) code published alongside the official announcement.

Company Overview

Jenburkt Pharmaceuticals Limited is registered under CIN: L24230MH1985PLC036541, with its registered office at Nirmala Apartments, 93, J. P. Road, Andheri (West), Mumbai – 400 058. The company, which marks 40 years of excellence in healthcare, operates under the tagline "Delivering Excellence in Life Sciences." The filing underscores the company's continued adherence to SEBI's listing and disclosure obligations.

Jenburkt pharmaceuticals Limited has formally disclosed to BSE Limited that it maintains its classification as 'not a large corporate' for the financial year ended March 31, 2026. The disclosure was made on April 14, 2026, in compliance with regulatory requirements.

Regulatory Compliance Disclosure

The company's disclosure was made pursuant to SEBI Circular SEBI/HO/DDHS/CIR/2021/613 dated August 10, 2021, which was subsequently updated on April 13, 2022. This circular establishes criteria for determining whether companies qualify as 'large corporates' under SEBI regulations.

Corporate Status Confirmation

Jenburkt Pharmaceuticals Limited confirmed that it does not meet the applicability criteria mentioned in Clause 2.1 of Chapter XII of the SEBI circular for classification as a large corporate entity. This status determination is significant for regulatory compliance and reporting requirements under SEBI guidelines.

Authorization and Documentation

The disclosure was jointly signed by two key executives of the company. Dilip H. Bhuta, Whole Time Director and CFO, digitally signed the document on April 14, 2026, at 12:46:54 +05'30'. Ashish R. Shah, Sr. Vice President and Company Secretary, also provided his digital signature on the same date at 11:38:52 +05'30'.

The formal communication was addressed to BSE Ltd. at P.J. Towers, Dalal Street, Mumbai - 400 001, requesting the exchange to take the disclosure on record as required by regulatory protocols.